Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Accelerate Diagnostics Stock Up 6.3 %

Accelerate Diagnostics stock opened at $5.61 on Thursday. Accelerate Diagnostics has a twelve month low of $4.50 and a twelve month high of $17.80. The firm has a 50 day moving average price of $6.70 and a 200-day moving average price of $6.94. The company has a market capitalization of $80.62 million, a P/E ratio of -0.77 and a beta of 1.18.

Get Accelerate Diagnostics alerts:

Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 10th. The medical research company reported ($2.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.86). The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.00 million. Equities analysts expect that Accelerate Diagnostics will post -6.46 EPS for the current fiscal year.

Institutional Trading of Accelerate Diagnostics

A number of institutional investors have recently modified their holdings of the business. Swiss National Bank lifted its stake in shares of Accelerate Diagnostics by 19.0% during the 1st quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock valued at $123,000 after buying an additional 13,600 shares in the last quarter. Virtu Financial LLC lifted its stake in Accelerate Diagnostics by 95.4% in the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock worth $25,000 after purchasing an additional 17,461 shares in the last quarter. Bank of Montreal Can purchased a new stake in Accelerate Diagnostics in the 1st quarter worth approximately $27,000. Cubist Systematic Strategies LLC purchased a new stake in Accelerate Diagnostics in the 3rd quarter worth approximately $29,000. Finally, HighTower Advisors LLC lifted its stake in Accelerate Diagnostics by 115.6% in the 1st quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock worth $53,000 after purchasing an additional 20,000 shares in the last quarter.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Articles

• Five stocks we like better than Accelerate Diagnostics
• 10 Best Airline Stocks to Buy
• 52-week Low Names To Tip The Upside Scale In Your Favor
• Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
• KB Home Price Weakness is a Signal to Buy this Cash Machine
• How Technical Indicators Can Help You Find Oversold Stocks 
• Analysts Went All In On These Computer Stocks, Save Your Spot

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.